Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers

Phase 1 Completed 86 enrolled Shattuck Labs, Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

SL03-OHD-105 is an open-label, multicenter, phase 1b trial designed to evaluate SL-172154 administered in combination with pegylated liposomal doxorubicin (PLD) or mirvetuximab soravtansine (MIRV) in patients with platinum resistant ovarian cancer. Approximately 102 patients will be enrolled in this study.

Timeline

Start: 2022-08-18
Primary completion: 2025-02-07
Completion: 2025-02-07

Publications

Drew Y, Gilbert L, Martinez Bueno A, Oaknin A, Moreno V, Gaba Garcia L, Jayson GC, Kristeleit RS, Lakhani N, Banerjee S, Matei D, Oza A, Miller R, Yiannakis D, Barretina-Ginesta MP, Martinez Garcia J, Wang G, Miriyala J, Franke A, Galvez E, Pandite L, Richardson DL. Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. Br J Cancer. 2026 Jun;134(12):1754-1763. doi: 10.1038/s41416-026-03430-0. Epub 2026 Apr 8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mirvetuximab	Monoclonal antibody	—	Intravenous
Subject	Pegylated liposomal doxorubicin	Unknown	—	Intravenous
Subject	SL-172154	Protein / enzyme biologic	3 mg/kg	Intravenous

Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers

Summary

Timeline

Publications

Drugs

Indications